Rifadin and Romidepsin Injection

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using romiDEPsin together with rifAMPin is generally not recommended. Combining these medications may significantly increase the blood levels and effects of romiDEPsin. You may be more likely to experience side effects such as anemia, bleeding problems, infections, or an irregular heart rhythm that may be serious or life-threatening. Contact your doctor if you develop paleness, fatigue, dizziness, fainting, unusual bruising or bleeding, fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. You should seek immediate medical attention if you experience sudden dizziness, lightheadedness, fainting, shortness of breath, or fast or pounding heartbeats during treatment with romiDEPsin. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: Coadministration with rifampin may significantly increase the plasma concentrations and pharmacologic effects of romidepsin. The exact mechanism of interaction has not been established, but is likely due to rifampin inhibition of an undetermined hepatic uptake process that is important in the clearance of romidepsin. In patients with advanced cancer, administration of romidepsin 14 mg/m2 (4-hour infusion) with rifampin unexpectedly increased romidepsin peak plasma concentration (Cmax) and systemic exposure (AUC) by 60% and 80%, respectively, compared to romidepsin administered alone. In addition, rifampin decreased romidepsin clearance by 44% and volume of distribution by 52%. The potential for increased risk of hematologic toxicities such as anemia, leukopenia, and thrombocytopenia as well as electrocardiographic changes such as QT interval prolongation and T-wave and ST-segment changes should be considered.

MANAGEMENT: The use of romidepsin in combination with rifampin should generally be avoided.

Rifadin

Generic Name: rifampin

Brand name: Rifadin, Rifadin IV, Rimactane

Synonyms: n.a.

What is Rifadin?

Romidepsin Injection

Generic Name: romidepsin

Brand name: Istodax

Synonyms: Romidepsin, RomiDEPsin

What is Romidepsin Injection?